Please ensure Javascript is enabled for purposes of website accessibility

Why Endo International plc Jumped Higher Today

By Brian Orelli, PhD – Sep 23, 2016 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker gets a new boss.

Image source: Getty Images.

What happened

Endo International (ENDP 9.83%) is up 15% at 3:17 p.m. EDT after the drugmaker announced that Paul Campanelli is taking over as president and CEO.

So what

Campanelli, who was previously the president of Par Pharmaceuticals -- Endo's generic and OTC drugs business -- takes over for Rajiv De Silva. Campanelli was CEO of Par Pharmaceuticals before Endo acquired the company, so he has experience at the top.

Of course, this isn't so much an endorsement of Campanelli as a sign that investors weren't happy with the performance of Endo under De Silva's leadership. Shares are down 69% over the last year.

ENDP Chart

ENDP data by YCharts

In addition to announcing the leadership change, Endo also reaffirmed its guidance of third quarter revenues between $830 million and $870 million and adjusted earnings between $0.77 and $0.82 per share. With just seven days left in the quarter, Endo should have a good idea where the top and bottom lines of the earnings report will fall. The company also reaffirmed its full-year guidance.

Now what

While meeting guidance is always nice, keep in mind that management lowered the bar in May, cutting full-year revenue guidance by 11% from its former high-end guidance and adjusted earnings per share guidance by 23%.

Campanelli isn't going to be able to turn Endo around overnight, but it seems reasonable that the shakeup makes the company worth a little more today.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Endo International Stock Quote
Endo International
$0.11 (9.83%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.